Study guide

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis

Key Takeaways Explain This Topic AI

Normal vaginal pH ranges from 3.8 to 4.5, maintained by lactic acid- and hydrogen peroxide-producing Lactobacillus species that colonize estrogen-stimulated squamous epithelium.

Bacterial vaginosis is diagnosed clinically using Amsel criteria (at least 3 of 4: thin homogeneous discharge, pH >4.5, positive whiff test, clue cells >20%) and treated with oral metronidazole 500 mg twice daily for 7 days or topical therapies.

Vulvovaginal candidiasis presents with normal pH (3.8-4.5), negative whiff test, and pseudohyphae/blastospores on 10% KOH; uncomplicated cases respond to single-dose oral fluconazole 150 mg, while azole-resistant C. glabrata requires intravaginal boric acid.

CDC advises against oral fluconazole in pregnancy because even a single 150 mg dose has been linked to spontaneous abortion and congenital anomalies; 7-day topical azole regimens are recommended.

Trichomoniasis is diagnosed with high sensitivity using NAAT; updated CDC guidelines mandate oral metronidazole 500 mg twice daily for 7 days (superseding the single 2 g dose) along with expedited partner therapy.

Last updated: October 2026

Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis

Vulvovaginitis represents a leading reason women seek outpatient gynecologic care. Vaginal health relies on a homeostatic ecosystem governed by estrogen, glycogen, and hydrogen peroxide-producing Lactobacillus species (mainly L. crispatus and L. jensenii ). These commensals maintain an acidic vaginal pH between 3.8 and 4.5, inhibiting pathogens. Physiologic leukorrhea consists of squames, transudate, and lactobacilli, presenting as clear or white, odorless discharge with pH <= 4.5 and no inflammatory leukocytes. When disrupted, pathological vaginitis results. The three predominant causes are Bacterial Vaginosis (BV), Vulvovaginal Candidiasis (VVC), and Trichomoniasis.

Important

Collect diagnostic secretions from lateral vaginal walls using a non-lubricated speculum. Avoid cervical mucus; cervical secretions are naturally alkaline (pH > 7.0) and produce false-positive elevations on vaginal pH testing.

Differential Diagnosis Matrix

Differentiating vulvovaginitis requires integrating physical findings, vaginal pH, the 10% potassium hydroxide (KOH) whiff test, and microscopy.

Diagnostic Parameter Bacterial Vaginosis (BV) Vulvovaginal Candidiasis (VVC) Trichomoniasis

Etiology Polymicrobial dysbiosis ( Gardnerella , anaerobes) Candida albicans (85–90%), C. glabrata Trichomonas vaginalis (flagellated protozoan)

Vaginal pH Elevated (>4.5, typically 5.0–5.5) Normal acidic (3.8–4.5) Markedly elevated (>4.5, often 5.5–6.5)

Discharge Thin, homogeneous, gray-white, adherent Thick, white, curdy ("cottage cheese"), adherent Copious, frothy, yellow-green, malodorous

Whiff Test Positive (fishy amine odor with 10% KOH) Negative Frequently positive

Microscopy Clue cells (>20%), absent lactobacilli, few WBCs Pseudohyphae and budding yeast on 10% KOH Motile flagellated trichomonads, WBCs >10/HPF

Primary Symptoms Fishy malodor (worse post-coitus or menses) Intense vulvar pruritus, burning, dyspareunia Copious discharge, irritation, postcoital spotting

  • Cervical Exam Normal, non-inflamed Normal or mild erythema Colpitis macularis ("strawberry cervix" in 2–5%)
  • Bacterial Vaginosis (BV)

Bacterial vaginosis is a non-inflammatory dysbiosis marked by lactobacilli depletion and overgrowth of anaerobes, including Gardnerella vaginalis , Atopobium vaginae , Prevotella , and Mobiluncus . Microbial decarboxylases convert amino acids into volatile amines (putrescine, cadaverine), generating a distinct fishy odor.

Diagnostic Criteria

Clinical diagnosis requires at least three of four Amsel criteria :

Thin, homogeneous, gray-white discharge adhering smoothly to vaginal walls.

Vaginal pH greater than 4.5.

Positive whiff test (fishy amine odor upon adding 10% KOH to secretions).

Clue cells accounting for >=20% of vaginal epithelial cells on saline wet mount (squamous cells stippled with adherent bacteria obscuring borders).

In specialized research settings, the Gram stain-based Nugent score serves as the gold standard (scored 0–10: 0–3 normal Lactobacillus flora; 4–6 intermediate; 7–10 bacterial vaginosis).

Pharmacotherapy

Treatment is indicated for all symptomatic women, and for asymptomatic patients undergoing surgical abortion or upper tract instrumentation.

First-Line Regimens: Oral metronidazole 500 mg twice daily for 7 days; intravaginal metronidazole 0.75% gel, one applicator (5 g) daily at bedtime for 5 days; or intravaginal clindamycin 2% cream, one applicator (5 g) at bedtime for 7 days.

Clinical Considerations: The 2021 CDC guidelines state that abstaining from alcohol while taking metronidazole is unnecessary, because the disulfiram-like reaction is not supported by evidence (older labeling still carries the warning). Clindamycin cream is oil-based and can weaken latex condoms and diaphragms for 5 days after use. CDC 2021 did not recommend routine partner treatment, but after a 2025 randomized trial nearly halved recurrence, ACOG (October 2025) supports offering concurrent treatment to the male partner of a patient with recurrent BV in a monogamous relationship: oral metronidazole 400 mg twice daily plus 2% clindamycin cream applied to the penis twice daily, both for 7 days.

Vulvovaginal Candidiasis (VVC)

Vulvovaginal candidiasis affects up to 75% of women. Candida albicans accounts for roughly 90% of infections, with non-albicans species such as Candida glabrata causing the remainder.

Classification & Diagnostics

VVC is divided into uncomplicated and complicated presentations:

Uncomplicated VVC: Sporadic, mild-to-moderate episodes caused by C. albicans in healthy, non-pregnant, immunocompetent hosts.

Complicated VVC: Recurrent infections (>=4 episodes in 12 months), severe inflammation (edema, fissures, excoriations), non-albicans species, or occurring with uncontrolled diabetes, immunosuppression, or pregnancy.

Microscopy reveals budding blastospores and branching pseudohyphae on 10% KOH prep. Vaginal pH remains normal (3.8–4.5), and the whiff test is negative.

Treatment Strategies

Uncomplicated VVC: Oral fluconazole 150 mg single dose, or short-course topical azoles (such as miconazole 2% cream or clotrimazole 1% cream for 7 days).

Recurrent VVC: Oral fluconazole 150 mg every 72 hours for 3 doses (days 1, 4, 7), followed by weekly maintenance fluconazole 150 mg for 6 months.

Non-albicans ( C. glabrata ): Often fluconazole-resistant. CDC recommends a longer (7–14 day) course of a non-fluconazole azole first; for recurrence or treatment failure, use intravaginal boric acid 600 mg in a gelatin capsule once daily for 21 days.

Pregnancy Considerations: Oral fluconazole is contraindicated due to miscarriage and teratogenicity risks. Only 7-day topical azoles are permitted. Boric acid is strictly contraindicated in pregnancy and fatal if ingested orally.

Trichomoniasis

Trichomonas vaginalis is a sexually transmitted, flagellated anaerobic protozoan infecting the squamous epithelium of the vagina, urethra, and Skene's glands.

Clinical Presentation & Diagnostics

Patients report copious, malodorous, purulent, yellow-green frothy discharge, vulvar irritation, dysuria, and postcoital bleeding. Speculum examination may reveal cervical petechiae ("strawberry cervix"). Vaginal pH is elevated (>4.5, typically 5.5–6.5).

While wet mounts identify motile trichomonads, sensitivity is poor (50–60%). Nucleic Acid Amplification Testing (NAAT) is the gold standard, demonstrating sensitivity and specificity above 95–100%.

Treatment & Partner Management

Updated CDC Regimen: Oral metronidazole 500 mg twice daily for 7 days. Randomized trials confirmed this 7-day course achieves superior cure rates in women compared to the historic single 2 g dose. Tinidazole 2 g orally in a single dose is an alternative.

Expedited Partner Therapy (EPT): All sexual partners should be treated concurrently to prevent reinfection. Patients should abstain from intercourse until they and their partners have completed treatment and symptoms have resolved.

Rescreening: Repeat NAAT screening is mandatory 3 months after completing therapy due to high reinfection rates.